LTR Pharma (ASX:LTP) ROCE % : -29.86% (As of Dec. 2024)

View and export this data going back to 2023. Start your Free Trial

What is LTR Pharma ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. LTR Pharma's annualized ROCE % for the quarter that ended in Dec. 2024 was -29.86%.

LTR Pharma ROCE % Historical Data

The historical data trend for LTR Pharma's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LTR Pharma ROCE % Chart

LTR Pharma Annual Data

Trend

Jun21

Jun22

Jun23

Jun24

ROCE %

-118.87

-31.43

-133.36

LTR Pharma Semi-Annual Data
	Jun21	Jun22	Jun23	Dec23	Jun24	Dec24
ROCE %	Get a 7-Day Free Trial			-	-	-73.72	-191.54	-29.86

LTR Pharma ROCE % Calculation

LTR Pharma's annualized ROCE % for the fiscal year that ended in Jun. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Jun. 2024 )		(A: Jun. 2023 )		(A: Jun. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Jun. 2024 )		(A: Jun. 2023 )		(A: Jun. 2024 )
	=	-6.954	/	( ( (7.51 - 0.021)	+	(3.369 - 0.429) )	/ 2 )
	=	-6.954	/	( (7.489	+	2.94)	/ 2 )
	=	-6.954	/	5.2145
	=	-133.36 %

LTR Pharma's ROCE % of for the quarter that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2024 )		(Q: Jun. 2024 )		(Q: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2024 )		(Q: Jun. 2024 )		(Q: Dec. 2024 )
	=	-5.56	/	( ( (3.369 - 0.429)	+	(34.732 - 0.433) )	/ 2 )
	=	-5.56	/	( ( 2.94	+	34.299 )	/ 2 )
	=	-5.56	/	18.6195
	=	-29.86 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2024) EBIT data.

LTR Pharma (ASX:LTP) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

LTR Pharma ROCE % Related Terms

Thank you for viewing the detailed overview of LTR Pharma's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

LTR Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LTR Pharma Ltd (ASX:LTP) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

9A/204 Alice Street, Brisbane, QLD, AUS, 4000

Website

https://www.ltrpharma.com

LTR Pharma Ltd is a clinical stage pharmaceutical company focused on holistically improving men's health, physically and mentally, through the commercialization of an intranasal spray treatment for Erectile Dysfunction. SPONTAN is a Vardenafil-based nasal delivery formulation designed to be a lower dose fast-acting administration that provides a rapid and high availability to a patient's bloodstream compared with the incumbent oral ED treatment products on the market.

LTR Pharma Headlines

No Headlines